United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - vortioxetine hydrobromide (unii: tks641koay) (vortioxetine - unii:3o2k1s3wqv) - vortioxetine 5 mg - trintellix is indicated for the treatment of major depressive disorder (mdd) in adults. - hypersensitivity to vortioxetine or any component of the formulation. hypersensitivity reactions including anaphylaxis, angioedema, and urticaria have been reported in patients treated with trintellix [see adverse reactions (6.2)] . - the use of maois intended to treat psychiatric disorders with trintellix or within 21 days of stopping treatment with trintellix is contraindicated because of an increased risk of serotonin syndrome. the use of trintellix within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.4), warnings and precautions (5.2)] . starting trintellix in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see warnings and precautions (5.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monit

United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - vortioxetine hydrobromide (unii: tks641koay) (vortioxetine - unii:3o2k1s3wqv) - trintellix is indicated for the treatment of major depressive disorder (mdd) in adults. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for antidepressants at 1-844-405-6185 or visiting online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/. risk summary there are limited human data on trintellix use during pregnancy to inform any drug-associated risks. however, there are clinical considerations regarding neonates exposed to ssris and snris, including trintellix, during the third trimester of pregnancy [see clinical considerations] . vortioxetine administered to pregnant rats and rabbits during the period of organogenesis at doses ≥15 times and 10 times the maximum recommended human dose (mrhd), respectively, resulted in decreased fetal body weight and del

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - vortioxetine hydrobromide (unii: tks641koay) (vortioxetine - unii:3o2k1s3wqv) - trintellix is indicated for the treatment of major depressive disorder (mdd) in adults. - hypersensitivity to vortioxetine or any component of the formulation. hypersensitivity reactions including anaphylaxis, angioedema, and urticaria have been reported in patients treated with trintellix [see adverse reactions (6.2)] . - the use of maois intended to treat psychiatric disorders with trintellix or within 21 days of stopping treatment with trintellix is contraindicated because of an increased risk of serotonin syndrome. the use of trintellix within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.4), warnings and precautions (5.2)] . starting trintellix in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk o

Singapore - English - HSA (Health Sciences Authority)

international contact lens pte. ltd. - ophthalmology - it is indicated for the correction of myopia and hyperopia. the lens is intended for single patient use and for daily wear.

Singapore - English - HSA (Health Sciences Authority)

international contact lens pte. ltd. - ophthalmology - indicated for the correction of myopia and hyperopia. the lens is intended for single patient use and for daily wear.

Singapore - English - HSA (Health Sciences Authority)

international contact lens pte. ltd. - ophthalmology - indicated for the correction of myopia and hyperopia. the lens is intended for single patient use and for daily wear.

Singapore - English - HSA (Health Sciences Authority)

point of care private limited - obstetrics & gynaecology - the hcg one step pregnancy test is a rapid, one step test for the qualitative detection of human chorionic gonadotropin (hcg) in urine, as an aid for the early detection of pregnancy. the test is intended for in vitro diagnostic self-testing.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - prasterone, quantity: 6.5 mg - pessary - excipient ingredients: hard fat - intrarosa is indicated for the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - soya oil, quantity: 6 g/l; olive oil, quantity: 24 g/l - injection, intravenous infusion - excipient ingredients: nitrogen; water for injections; sodium hydroxide; egg lecithin; sodium oleate; glycerol - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - propofol, quantity: 10 g/l - injection, emulsion - excipient ingredients: medium chain triglycerides; water for injections; glycerol; sodium hydroxide; soya oil; egg lecithin; oleic acid - induction of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older.,maintenance of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older.,fresofol (1 percent) mct / lct may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided.,fresofol (1 percent) mct / lct has no analgesic properties. ,sedation during intensive care in adults,fresofol (1 percent) mct / lct may also be used in adults for sedation of ventilated patients receiving intensive care.,conscious sedation for surgical and diagnostic procedures in adults,fresofol (1 percent) mct / lct may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.